Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxRestructuring CostsRevenueSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

Pediatrix Medical (MD) Income towards Parent Company: 2009-2025

Historic Income towards Parent Company for Pediatrix Medical (MD) over the last 16 years, with Q3 2025 value amounting to $71.7 million.

  • Pediatrix Medical's Income towards Parent Company rose 26884.93% to $71.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $162.2 million, marking a year-over-year increase of 22519.2%. This contributed to the annual value of $3.8 million for FY2022, which is 8358.61% down from last year.
  • As of Q3 2025, Pediatrix Medical's Income towards Parent Company stood at $71.7 million, which was up 26884.93% from $39.3 million recorded in Q2 2025.
  • Pediatrix Medical's Income towards Parent Company's 5-year high stood at $71.7 million during Q3 2025, with a 5-year trough of -$153.0 million in Q2 2024.
  • Its 4-year average for Income towards Parent Company is $4.0 million, with a median of $5.7 million in 2022.
  • As far as peak fluctuations go, Pediatrix Medical's Income towards Parent Company surged by 586995.31% in 2021, and later plummeted by 17961.14% in 2022.
  • Over the past 4 years, Pediatrix Medical's Income towards Parent Company (Quarter) stood at $7.2 million in 2021, then dropped by 21.77% to $5.7 million in 2022, then skyrocketed by 438.61% to $30.5 million in 2024, then soared by 135.26% to $71.7 million in 2025.
  • Its Income towards Parent Company was $71.7 million in Q3 2025, compared to $39.3 million in Q2 2025 and $20.7 million in Q1 2025.